Comparison of Antiemetic Effectiveness of Palonosetron Versus Ondansetron in Patients on Cancer Chemotherapy: A Prospective Observational Study in South Indians
Introduction: Chemotherapy Induced Nausea and Vomiting (CINV) is the most distressing side effect of cancer chemotherapy. It can seriously produce an impact on patient's quality of life. Prevention of CINV is far more effective than treatment of an established CINV. If the patient receives...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
JCDR Research and Publications Private Limited
2017-05-01
|
| Series: | Journal of Clinical and Diagnostic Research |
| Subjects: | |
| Online Access: | https://jcdr.net/articles/PDF/9818/25129_CE[Ra]_F(Sh)_PF1(SY_SS)_PFA(P_SY).pdf |
| _version_ | 1818805846509879296 |
|---|---|
| author | Abdul Aslam Parathoduvil Asha Sisupalan Padanayil Lekshmikutty Rema |
| author_facet | Abdul Aslam Parathoduvil Asha Sisupalan Padanayil Lekshmikutty Rema |
| author_sort | Abdul Aslam Parathoduvil |
| collection | DOAJ |
| description | Introduction: Chemotherapy Induced Nausea and Vomiting
(CINV) is the most distressing side effect of cancer chemotherapy.
It can seriously produce an impact on patient's quality of life.
Prevention of CINV is far more effective than treatment of an
established CINV. If the patient receives an optimal antiemetic
regimen during the initial course of chemotherapy, the
likelihood of developing emesis is greatly reduced. Although,
all first generation 5HT3 antagonists demonstrate reasonable
efficacy in preventing acute CINV, delayed CINV still remains a
problem.
Aim: To compare the effectiveness and safety of palonosetron
versus ondansetron as an antiemetic agent in patients receiving
cancer chemotherapy.
Materials and Methods: A prospective observational study
was conducted in 106 patients in each treatment arm. Study
duration was 12 months from January 2013 to January 2014.
Consecutive patients diagnosed with cancer satisfying inclusion
criteria, who were about to receive moderately or highly
emetogenic chemotherapy were enrolled into the study after
getting informed written consent. Each patient received either
Intravenous (IV) palonosetron 0.25 mg or ondansetron 8 mg
half an hour before chemotherapy as antiemetic. Patients were
followed up for a period of five days following chemotherapy.
Number of episodes, severity of vomiting and nausea and
antiemetic rescue given if any were recorded. The data were
graded using NCI-CTCAE (VERSION 3.0). Proportion of patients
with nausea and vomiting during acute (0-24 hours), delayed
(24-120 hours) and overall period (0-120 hours) in both the
study groups were compared. Outcome was assessed in terms
of symptom control and response. Data were analysed using
SPSS-16.0 statistical software (IBM). Chi-square test was used
to compare the difference in clinical response.
Results: Complete response during acute phase in ondansetron
group was 80.2%, while for palonosetron it was 89.6%. During
delayed phase, ondansetron and palonosetron produced
complete response in 70.8% and 86.8% respectively. A total of
65.1% and 82.1% of subjects experienced complete response
during the overall period in the ondansetron and palonosetron
groups respectively. The difference in the response to antiemetic
prophylaxis was statistically significant between the two groups
for delayed (p-value = 0.006) and overall phase (p-value =
0.008).
Conclusion: Palonosetron is clinically more efficacious than
ondansetron in controlling CINV especially in delayed phase
and overall period of emesis. |
| first_indexed | 2024-12-18T19:00:22Z |
| format | Article |
| id | doaj.art-6bc3a61a9f2e4a5fadb49e03fb5b8461 |
| institution | Directory Open Access Journal |
| issn | 2249-782X 0973-709X |
| language | English |
| last_indexed | 2024-12-18T19:00:22Z |
| publishDate | 2017-05-01 |
| publisher | JCDR Research and Publications Private Limited |
| record_format | Article |
| series | Journal of Clinical and Diagnostic Research |
| spelling | doaj.art-6bc3a61a9f2e4a5fadb49e03fb5b84612022-12-21T20:56:30ZengJCDR Research and Publications Private LimitedJournal of Clinical and Diagnostic Research2249-782X0973-709X2017-05-01115FC10FC1410.7860/JCDR/2017/25129.9818Comparison of Antiemetic Effectiveness of Palonosetron Versus Ondansetron in Patients on Cancer Chemotherapy: A Prospective Observational Study in South IndiansAbdul Aslam Parathoduvil0Asha Sisupalan1Padanayil Lekshmikutty Rema2Assistant Professor, Department of Pharmacology, Travancore Medical College, Kollam, Kerala, India.Professor and Head, Department of Pharmacology, Government Medical College, Manjeri, Kerala, India.Professor and Head, Department of Radiotherapy, Government Medical College, Kottayam, Kerala, India.Introduction: Chemotherapy Induced Nausea and Vomiting (CINV) is the most distressing side effect of cancer chemotherapy. It can seriously produce an impact on patient's quality of life. Prevention of CINV is far more effective than treatment of an established CINV. If the patient receives an optimal antiemetic regimen during the initial course of chemotherapy, the likelihood of developing emesis is greatly reduced. Although, all first generation 5HT3 antagonists demonstrate reasonable efficacy in preventing acute CINV, delayed CINV still remains a problem. Aim: To compare the effectiveness and safety of palonosetron versus ondansetron as an antiemetic agent in patients receiving cancer chemotherapy. Materials and Methods: A prospective observational study was conducted in 106 patients in each treatment arm. Study duration was 12 months from January 2013 to January 2014. Consecutive patients diagnosed with cancer satisfying inclusion criteria, who were about to receive moderately or highly emetogenic chemotherapy were enrolled into the study after getting informed written consent. Each patient received either Intravenous (IV) palonosetron 0.25 mg or ondansetron 8 mg half an hour before chemotherapy as antiemetic. Patients were followed up for a period of five days following chemotherapy. Number of episodes, severity of vomiting and nausea and antiemetic rescue given if any were recorded. The data were graded using NCI-CTCAE (VERSION 3.0). Proportion of patients with nausea and vomiting during acute (0-24 hours), delayed (24-120 hours) and overall period (0-120 hours) in both the study groups were compared. Outcome was assessed in terms of symptom control and response. Data were analysed using SPSS-16.0 statistical software (IBM). Chi-square test was used to compare the difference in clinical response. Results: Complete response during acute phase in ondansetron group was 80.2%, while for palonosetron it was 89.6%. During delayed phase, ondansetron and palonosetron produced complete response in 70.8% and 86.8% respectively. A total of 65.1% and 82.1% of subjects experienced complete response during the overall period in the ondansetron and palonosetron groups respectively. The difference in the response to antiemetic prophylaxis was statistically significant between the two groups for delayed (p-value = 0.006) and overall phase (p-value = 0.008). Conclusion: Palonosetron is clinically more efficacious than ondansetron in controlling CINV especially in delayed phase and overall period of emesis.https://jcdr.net/articles/PDF/9818/25129_CE[Ra]_F(Sh)_PF1(SY_SS)_PFA(P_SY).pdfantiemetic prophylaxischemotherapy induced nausea and vomiting5ht3 receptor antagonists |
| spellingShingle | Abdul Aslam Parathoduvil Asha Sisupalan Padanayil Lekshmikutty Rema Comparison of Antiemetic Effectiveness of Palonosetron Versus Ondansetron in Patients on Cancer Chemotherapy: A Prospective Observational Study in South Indians Journal of Clinical and Diagnostic Research antiemetic prophylaxis chemotherapy induced nausea and vomiting 5ht3 receptor antagonists |
| title | Comparison of Antiemetic Effectiveness of Palonosetron Versus Ondansetron in Patients on Cancer Chemotherapy: A Prospective Observational Study in South Indians |
| title_full | Comparison of Antiemetic Effectiveness of Palonosetron Versus Ondansetron in Patients on Cancer Chemotherapy: A Prospective Observational Study in South Indians |
| title_fullStr | Comparison of Antiemetic Effectiveness of Palonosetron Versus Ondansetron in Patients on Cancer Chemotherapy: A Prospective Observational Study in South Indians |
| title_full_unstemmed | Comparison of Antiemetic Effectiveness of Palonosetron Versus Ondansetron in Patients on Cancer Chemotherapy: A Prospective Observational Study in South Indians |
| title_short | Comparison of Antiemetic Effectiveness of Palonosetron Versus Ondansetron in Patients on Cancer Chemotherapy: A Prospective Observational Study in South Indians |
| title_sort | comparison of antiemetic effectiveness of palonosetron versus ondansetron in patients on cancer chemotherapy a prospective observational study in south indians |
| topic | antiemetic prophylaxis chemotherapy induced nausea and vomiting 5ht3 receptor antagonists |
| url | https://jcdr.net/articles/PDF/9818/25129_CE[Ra]_F(Sh)_PF1(SY_SS)_PFA(P_SY).pdf |
| work_keys_str_mv | AT abdulaslamparathoduvil comparisonofantiemeticeffectivenessofpalonosetronversusondansetroninpatientsoncancerchemotherapyaprospectiveobservationalstudyinsouthindians AT ashasisupalan comparisonofantiemeticeffectivenessofpalonosetronversusondansetroninpatientsoncancerchemotherapyaprospectiveobservationalstudyinsouthindians AT padanayillekshmikuttyrema comparisonofantiemeticeffectivenessofpalonosetronversusondansetroninpatientsoncancerchemotherapyaprospectiveobservationalstudyinsouthindians |